IPP Bureau
LivaNova announces first patient implanted in OSPREY clinical study
By IPP Bureau - February 27, 2022
Study to evaluate effectiveness of hypoglossal nerve stimulation
Alps Pharma launches a new water soluble Isoquercetin
By IPP Bureau - February 27, 2022
Eubio Isoquercetin derived from Sophora Japonica is expected to deliver more Quercetin to the body via small doses of Isoquercetin.
Daewoong completes combination therapy of antidiabetic drug Enavogliflozin
By IPP Bureau - February 27, 2022
Confirmed positive phase 3 topline results in addition to Enavogliflozin monotherapy and Metformin combination therapy
HitGen completes research collaboration with MTPC
By IPP Bureau - February 27, 2022
Collaboration with MTPC to discover novel hit compounds for multiple drug targets
Cantex and Harvard's Wyss Institute to expand development of Azeliragon
By IPP Bureau - February 27, 2022
Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.
8 bulk drugs projects commissioned under PLI scheme
By IPP Bureau - February 26, 2022
The bulk drug plants that have already been commissioned include CDA, para amino phenol, atorvastatin, sulfadiazine, oxcarbazepine, levofloxacin, carbidopa and levodopa
IMI releases tamper evident caps with DoseID certified RFID
By IPP Bureau - February 26, 2022
Tamper evident caps with incorporated RFID technology offer a significant reduction in RFID implementation costs
Jean-Luc Herbeaux to become Hovione CEO
By IPP Bureau - February 26, 2022
Guy Villax was also involved with the EFCG and Rx-360 associations and contributed to legislation being passed on both sides of the Atlantic to fight fake medicines and to level the playing field for GMP manufacturing.
Japan approves Keytruda plus Lenvima for two types of cancer
By IPP Bureau - February 26, 2022
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
Wockhardt Hospitals, Mira Road opens centre for sports medicine
By IPP Bureau - February 25, 2022
The facility is spread across 215000 sq. feet and provides super-speciality care
Mandaviya launches ICMR/ DHR policy on biomedical innovation & entrepreneurship
By IPP Bureau - February 25, 2022
This policy will ensure multi-disciplinary collaboration, promote start-up culture and develop an innovation-led ecosystem at medical institutes across the country
USFDA grants Breakthrough Therapy Designation for Idiopathic Pulmonary Fibrosis therapy
By IPP Bureau - February 25, 2022
Boehringer Ingelheim plans to study this novel investigational therapy in patients with progressive fibrosing interstitial lung diseases
SK Biopharmaceuticals joins Pharmaceutical Supply Chain Initiative
By IPP Bureau - February 25, 2022
PSCI, a global non-profit organization, works with its members to ensure a positive environment that can improve global healthcare supply chains
Actu-Real and Jehangir Clinical Dev Centre announce strategic collaboration
By IPP Bureau - February 25, 2022
The joint initiative is called J-ARC Healthcare Solutions
Canada approves plant-based Covid-19 vaccine
By IPP Bureau - February 25, 2022
Medicago and GSK collaborated on Covifenz, an adjuvanted plant-based vaccine
